Denmark. Chr. Hansen Holding A/S
| Date of agreement: | 19 Feb 2013 |
|---|---|
| Country: | Denmark |
| Customer: | Chr. Hansen Holding A/S |
| Amount in EUR: | EUR 75 million |
| Maturity: | 7 years |
| NACE sector / loan type: | Research and development |
Project
The loan has been provided for financing an R&D programme focusing on the development and production of cultures, enzymes, probiotics and natural colours for the food, pharmaceutical and agricultural industries.
The R&D programme spanning 2012 to 2014 focuses on optimising the production process as well as on developing new innovative products.
Chr. Hansen A/S, founded in 1874, develops and supplies speciality ingredients to the global food and beverage, pharmaceutical and agriculture industries. The group operates in the cultures and enzymes, natural colours, and health and nutrition segments. The company has been listed on the NASDAQ OMX Copenhagen since 2010.
Fulfilment of NIB's mandate
The loan finances R&D expenditures in 2012–2014 for developing and producing cultures, enzymes, probiotics and natural colours for the food, pharmaceutical and agricultural industries. Cultures and enzymes are the company’s core business. Chr. Hansen is a frontrunner in probiotics and has a dominant market position in its global dairy cultures operations. Over 90 % of all R&D activities are concentrated in Denmark, where 300 employees are dedicated to innovation and technical applications. Extensive cooperation with universities in Denmark and research industries globally secure the ongoing development of bioscience and competencies within cultures and enzymes as well as its advanced application expertise.
Sustainability summary
The R&D efforts financed by the loan have been assessed as neutral from an environmental impact point of view. Chr. Hansen A/S has confirmed that their production as well as trade in pharmaceuticals are not on international phase-out or ban lists.
